QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Nordic RWD series Norway: where “cradle-to-grave” actually works
Norway closes our Nordic RWD series for a reason.
A universal healthcare system, personal identifiers, and decades of national coverage enable true longitudinal follow-up across care settings.
This is not just data availability.
It is data continuity.
Core Norwegian RWD pillars include:
▶️NorPD – complete outpatient prescription data
▶️ Norwegian Patient Registry – nationwide specialist care
▶️ Norwegian Registry for Primary Health Care – nationwide primary care data
▶️ […]
World EPA 2026: See you in Amsterdam
Quantify Research will be attending the World Evidence, Pricing and Access Congress in 📍Amsterdam, 📆 March 3–4.
Béranger Lueza, PhD & Abraham Choong will represent Quantify on site.
You will find us at Booth 302, together with our colleagues Pascale Holzerny, PhD, David Steinl, Susanne Bochat, and Ilda Theka, PhD, MBA from IGES Pharma, as part of the […]
Finland´s Registry Advantage: Decades of Linkable RWD
This is the third installment of the RWD sources from the Nordics. This week’s highlight is Finland’s real-world data ecosystem; which is built on something rare: continuity.
📆 Since the 1960s, nationwide health registries have captured longitudinal, population-level data across care settings. Today, these datasets can be securely linked using a unique personal identification number.
What does this enable in practice?
➡️ Nationwide follow-up from […]
Danish real-world data – what makes it unique?🔎
Denmark offers one of the world’s most robust environments for real-world evidence generation. Key strengths include:
1️⃣ Fast access to comprehensive data
The average time to fully process applications at the Danish Health Data Authority was ~40 days in November 2025, enabling rapid access to national-level data.
2️⃣ Rich clinical quality registries
With more than 80 nationwide clinical registries and 30 health and socioeconomic registries, […]